Evidence map›Paper›PMID 31637454›Full record

ArticleEuropean journal of clinical pharmacology2020

Pharmacological treatment patterns in heart failure: a population-based cohort study.

Pauline Bosco-Lévy, Clélia Favary, Jérémy Jové, Régis Lassalle, Nicholas Moore, Cécile Droz-Perroteau

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Pauline Bosco-LévyBordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, case 41, F-33076, Bordeaux CEDEX, France. pauline.bosco-levy@u-bordeaux.fr.ORCID http://orcid.org/0000-0001-9763-5974
Clélia FavaryBordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, case 41, F-33076, Bordeaux CEDEX, France.
Jérémy JovéBordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, case 41, F-33076, Bordeaux CEDEX, France.
Régis LassalleBordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, case 41, F-33076, Bordeaux CEDEX, France.
Nicholas MooreBordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, case 41, F-33076, Bordeaux CEDEX, France.
Cécile Droz-PerroteauBordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, case 41, F-33076, Bordeaux CEDEX, France.
Université de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the efficacy and safety of existing therapies of heart failure (HF) have been demonstrated in clinical trials, little is known about the treatment patterns in clinical practice, especially in France.

objectivesTo describe the treatment initiation patterns and the subsequent treatment changes among HF patients, in the first year following an incident hospitalization for HF, in a French real-world setting.

methodsA cohort of patients aged ≥ 40 years, with an incident hospitalization for HF between 01/01/2008 and 31/12/2013, was identified in the 1/97th permanent random sample of the French nationwide claims database and followed 1 year. HF drug exposure-beta blockers (BB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), aldosterone antagonists (AA), diuretics, digoxin, or ivabradine-was assessed quarterly using a Proportion of Days Covered ≥ 66% (≥ 60 days out of the 90 days of the quarter), by considering HF drugs individually or in combination. Drug changes were assessed between each quarter.

resultsBetween 2008 and 2013, 7387 patients were included. Their mean age was 77.7 years (± 12.0 years) and 51.6% were women. During the follow-up, 24.4% died, 20% were not exposed to any HF treatment, 48.3 to 43.2% had diuretics, one third had BB or ACEI, 9% had ARB or AA, 6% had digoxin, and 2% had ivabradine. The main change occurred between the first and the second quarter for 53.1% of the initially untreated patients.

conclusionThis study provides valuable information on treatment patterns after an initial hospitalization for HF.

Indexed as

Adrenergic beta-AntagonistsAdultAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCardiovascular AgentsClinical ProtocolsCohort StudiesDigoxinDiureticsDrug SubstitutionFemaleFranceHeart FailureHospitalizationAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCardiovascular AgentsDigoxinDiureticsIvabradineMineralocorticoid Receptor AntagonistsClaims databaseHeart failureTreatment patterns

Identifiers

PMID31637454
OpenAlexW2981842733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.